Posted On: 31 Oct 2023
The patent covers compositions and methods for treating KMA-expressing malignancies, including chimeric antigen receptors (CARs) and T cells containing CARs (CAR-T cells). The patent also covers methods and compositions comprising CAR-T cells co-expressing other anti-tumoral agents including cytokines and antibodies.
This patent has also been granted in Australia, USA, China, Russia and Japan and is under review in other jurisdictions.